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Abstract
Background: There is an increasing body of literature reporting treatment failure of the currently recommended radical
treatment of Plasmodium vivax infections. As P. vivax is the main malaria species outside the African continent, emerging
tolerance to its radical treatment regime could have major consequences in countries like Peru, where 80% of malaria cases
are due to P. vivax. Here we describe the results of a 1-year longitudinal follow up of 51 confirmed P. vivax patients living
around Iquitos, Peruvian Amazon, and treated according to the Peruvian national guidelines.
Methodology: Each month a blood sample for microscopy and later genotyping was systematically collected. Recent
exposure to infection was estimated by detecting antibodies against the P. vivax circumsporozoite protein (CSP) and all PCR
confirmed P. vivax infections were genotyped with 16 polymorphic microsatellites.
Results: During a 1-year period, 84 recurrent infections, 22 positive also by microscopy, were identified, with a median
survival time to first recurrent infection of 203 days. Most of them (71%) were asymptomatic; in 13 patients the infection
persisted undetected by microscopy for several consecutive months. The genotype of mostly recurrent infections differed
from that at day 0 while fewer differences were seen between the recurrent infections. The average expected
heterozygosity was 0.56. There was strong linkage disequilibrium (IA
s= 0.29, p,1.1024) that remained also when analyzing
only the unique haplotypes, suggesting common inbreeding.
Conclusion: In Peru, the P. vivax recurrent infections were common and displayed a high turnover of parasite genotypes
compared to day 0. Plasmodium vivax patients, even when treated according to the national guidelines, may still represent
an important parasite reservoir that can maintain transmission. Any elimination effort should consider such a hidden
reservoir.
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Introduction
In the Peruvian Amazon, after the eradication program was
abandoned in the 1980’s, malaria cases steadily increased to reach
a peak between 1995 and 1998, with 121 268 cases recorded in
1997, more than half due to Plasmodium falciparum [1,2]. Additional
efforts of the Peruvian National Malaria Control Program, from
1998 onwards, achieved a substantial reduction of the malaria
burden, though this was less pronounced for Plasmodium vivax [2,3].
Indeed, in 2009, among the 25 837 malaria cases recorded in the
Loreto department, 85% (n= 21 942) where due to P. vivax [4].
The ability to develop liver forms (hypnozoites) that may remain
dormant for weeks or even years before relapsing may partly
explain, despite vigorous control measures primarily aimed at P.
falciparum, the importance P. vivax has acquired in this setting.
Compliance to national treatment strategy for P. vivax malaria,
three-day chloroquine (CQ) (total dosage 25 mg/kg) and seven-
day primaquine (PQ) (total dosage of 210 mg/kg), is often
relatively low as symptoms usually disappear after three days
while the common occurrence of side effects by PQ reduces the
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motivation of the patients to complete the treatment [5]. In Brazil,
the risk of relapses in travelers after full treatment with CQ (1.5 g
over three days) and PQ (210 mg over 14 days) varied between 5
to 25%, with the majority occurring within the first six months [6].
Similarly, in endemic areas in Brazil and Colombia, such risk
varied between 6% and 18%, respectively [7,8,9]. More recently,
in Brazil, 36% patients having received full treatment of 1.5 g CQ
and 210 mg of PQ experienced recurrent P. vivax infections within
600 days, most of them occurring within the first 180 days [10]. It
is unclear if these observations are due to an increased tolerance of
P. vivax to PQ. Nevertheless, from the above studies there are some
indications that P. vivax strains from South America responds
poorly to the recommended PQ dosage, i.e. 15 mg/day for 14
days. Increasing the dosage to 30 mg/day for 14 days (total dosage
of 420 mg) has already been suggested [8].
There is currently little information on the P. vivax recurrence
rates in the Peruvian Amazon region where transmission is low
and clustered and asymptomatic infections are common [2]. In
2003, the P. vivax incidence in San Juan district was estimated at
0.39 infections/person/malaria seasons but has probably declined
since 2007 thanks to the malaria control efforts [2,4]. In order to
characterize the malaria burden in the Peruvian Amazon and
understand the dynamics of P. vivax infections, we analyzed blood
samples collected during 1-year follow-up in a cohort of patients
treated for a P. vivax clinical episode. All PCR-confirmed P. vivax
infections, symptomatic and asymptomatic, were genotyped to
determine the local dynamics of P. vivax clones in the Peruvian
Amazon. Concomitantly, to identify recent inoculations by
infected mosquitoes, the presence of antibodies against the
circumsporozoite protein (CSP) was measured using the CSP
Enzyme-Linked ImmunoSorbent Assay (ELISA). Results are
reported below.
Materials and Methods
Study sites and population
The study sites are situated at about three to seven kilometers
north of Iquitos, on the other bank of the Nanay River (Rio
Nanay) and include five neighboring villages, i.e. Manacamiri,
Lupuna, Fray Martin, San Pedro and Santa Rita, all being
accessible only by boat from Iquitos. These villages are located in a
densely forested region with many small pools, rivers and swamps,
offering ideal breeding sites for Anopheles darlingi, a sylvatic and
effective malaria vector [1–3]. Its biting activities occur near the
breeding sites and throughout the night, with an early peak
between 6 pm and midnight [1]. The climate is tropical, and
malaria transmission is perennial with a peak during the rainy
season, from November to May. Two health posts are located in
the study area: one in Manacamiri and the other in Lupuna
covering the remaining four villages. The population consists of
‘mestizos’ (individuals not belonging to a specific ethnic minority)
practicing mainly subsistence farming in forest fields situated at
easy walking or paddling distance all year around, with occasional
hunting and fishing [5].
Data collection
The cohort started in March 2008 and P. vivax infected patients
were recruited by active and passive case detection. Eligible
individuals with a P. vivax mono-infection were asked to participate
after signing (the parent/guardian for minors) an individual
informed consent. This study was approved by the Ethics Review
Board at Universidad Peruana Cayetano Heredia, Lima, Peru
(Project PVIVAX-UPCH, SIDISI code: 053256) and by both the
Institutional Review Board of the Institute of Tropical Medicine,
Antwerp, and the Ethical Committee of the University Hospital,
Antwerp, Belgium. Pregnant women, individuals with known
Glucose-6-Phosphate Dehydrogenase deficiency or known adverse
events to the treatment, chronic disease or bacterial infection,
neuropsychiatric disorders or malnutrition were excluded. All
patients included were treated according to the national
guidelines, i.e. CQ total 25 mg/kg over three days, and seven
days PQ, 0.50 mg/kg/day which started simultaneously with CQ
[11]. Patients were visited at home daily by the medical staff
attached to the project and the treatment was directly supervised.
After drug intake, each patient was observed during one hour. If
vomiting occurred during the first 30 minutes, a full dose was re-
administered and only half dose, if vomiting occurred 30 minutes
after drug intake. After completing the treatment patients were
weekly visited until day 28. During these visits blood samples were
collected. For the next 11 months, patients were visited monthly at
home, regardless of any treatment received during the follow up.
At each visit, patients were asked about clinical signs and
symptoms, and of any adverse events. A blood sample for
microscopy (thick and thin film) and a blood spot on filter paper
(Whatman grade 3, Whatman, Springfield Mill, USA) for later
molecular (PCR diagnosis and microsatellites genotyping) and
serological analysis (CSP ELISA) were systematically collected.
Malaria infections detected during the follow up were treated with
3 days of CQ 10 mg/kg 1st and 2nd day and 5 mg/kg 3rd day.
Laboratory methods
All filter paper blood spots collected at day 0 (before treatment)
and during the monthly visits were selected. DNA extraction was
performed with the saponine-chelex method and then analyzed by
species-specific PCR [12,13]. Positive samples positive were then
selected for genotyping using 16 microsatellites as previously
described [14]. The PCR product size was analyzed on a 3730 XL
ABI sequencer (Applied Biosystems, Foster city, California, USA).
Fragment sizes were determined with Genemapper (Applied
Biosystems, Foster city, California, USA) using default microsat-
ellite settings, whereby bands smaller than 100 relative fluores-
cence units (rfu) were defined as background. For one locus,
MS16, the rule was adapted because of stutter: for each sample,
only the peaks above 25% of the dominant one (highest rfu) were
considered as real alleles [14]. Samples for which we obtained no
amplification in some loci were re-analyzed to complete the
haplotypes.
The presence of antibodies to the circumsporozoite protein
(CSP), expressed during the sporozoite stage, was assessed in
patients’ sera by Enzyme-Linked ImmunoSorbent Assay (ELISA)
using three different long synthetic CS peptides (N-, R- and C-
polypeptide) [15]. All three peptides are reported to contain B-cell
epitopes and antibodies are generated against these regions in
natural infection [15]. The R-polypeptide corresponded to the
VK210 type of the CSP protein. One half of the micro plates
(Costar EIA/RIA Plate, Corning, New York, USA) were coated
with 1 mg/ml peptide and incubated overnight at 4uC. The whole
plates were blocked with 5% skim milk in PBS pH 7.4 for two
hours at room temperature. After washing, 100 ml of serum
samples diluted 1/200 times in PBS-Tween220 0.05% and 2.5%
skimmed milk was added in duplicate on each half of the plate and
incubated for one hour at room temperature. Human IgG
antibodies bound to the coated peptides were detected by adding
100 ml/well of phosphatase-conjugated polyvalent anti-human
immunoglobulin’s (Sigma Aldrich, St Louis MO, USA) at a
dilution of 1:1000. The enzymatic activity was developed after
incubation for 45 minutes at room temperature with 100 ml/well
para-nitrophenyl phosphate substrate (Sigma Aldrich Co., St Louis
Common P. vivax Recurrences after Radical Treatment
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MO, USA) and stopped with 50 ml/well 12% NaOH. Absorbance
was measured at 405 nm in a Microplate Reader (Multiskan
Ascent, Thermo Electron Corporation, Vantaa, Finland).
The corrected optical density (OD) of each sample was
calculated by subtracting the background OD from the corre-
sponding non-coated wells. Duplicates for which the OD values
differed by more than 30% were rejected for the analysis and
retested. Otherwise, the median was taken as the final result. Sera
from healthy individuals living in Belgium without any history of
stay in endemic areas were used as negative controls. The cut-off
value for sero-positivity was set as the cumulative mean plus three
standard deviations of all the negative control values. Samples
were considered positive if the OD of any of the three peptides was
higher than the cut-off value.
Data analysis
Data were entered and cleaned in Excel (Microsoft cooperation,
USA) then analyzed with Stata.10 (Stata Release 10, StataCorp,
College station, USA). A P. vivax recurrence was defined as any P.
vivax blood infection (symptomatic and asymptomatic) identified
after radical treatment by PCR (regardless of symptoms) and
occurring between day 28 and month 12. A patient was classified
as symptomatic if he/she had fever ($37.5uC) or history of fever at
the time of collection or in the previous 48 hours. Plasmodium vivax
recurrences were defined as ‘‘patent’’ or ‘‘sub-patent’’ depending
on whether the infection was diagnosed either by both microscopy
and PCR (patent) or only by PCR (sub-patent). As an estimate of
transmission potential due to P. vivax carriage, the person-infected
month (PIM) rate, i.e. months with P. vivax infection (either by
microscopy and/or PCR) divided by months of follow-up, was
computed and expressed in 100 person-months. Kaplan-Meier
survival curves were used to estimate the probability of having a P.
vivax recurrence in the first year after radical cure treatment. The
logrank test was used to compare the different curves.
Prevalence and levels of antibodies against the P. vivax CSP were
used to determine the risk for new P. vivax infections. Recent
exposure to P. vivax sporozoites was defined as seroconversion
(from negative to positive) or, in case of a positive test, at least 50%
increase of the corrected OD value between two consecutive
monthly samples.
Within each patient, the genetic profile of each recurrent episode
was first compared to the one at day-0 and later with all previous
episodes as described in [14], and classified into following
categories: i) fully related: all alleles in all loci of the current infection
present in at least one of the previous episodes/infections (including
day 0); ii) incomplete: as above but with alleles missing in one or more
loci; iii) unrelated: at least one locus completely different from any of
the previous episodes/infections, including day 0.
An infection was defined as polyclonal if there was at least one
locus with more than one allele. For each malaria infection, the
locus with the highest number of alleles was considered as a proxy
for the multiplicity of infection (MOI), representing the minimal
number of parasite haplotypes in the sample. The MOI and the
average number of allele per locus were assessed for day 0 and
samples collected during monthly follow up.
The parasite population characteristics were assessed only in
samples with monoclonal infections. The number of alleles/locus,
the allelic richness, and the genetic diversity of each locus were
computed for each population. Genetic diversity was assessed by
calculating the expected heterozygosity (He) = [n/(n-1)][12gpi
2],
where n is the total number of alleles, pi is the frequency of the i
th
allele in the population. The He represents the probability of
finding a different allele for a given locus in any pair of haploids
randomly drawn from the same population, and it was computed
with FSTAT version 2.9.3 [16]. Genetic differentiation (h)
between day 0 and monthly follow up samples was measured in
FSTAT using the method of Cockerham &Weir [16]. To evaluate
the likelihood that identical haplotypes found in two or more
samples originated from a different ancestry the psex values were
computed using GenClone ver. 2.0 [17]. This program test
whether all samples with identical haplotypes belong to the same
genetic clone. The allelic frequencies for a locus was estimated by
taking a sample pool composed of all the genotypes distinguished
by all loci except the one being estimated and this procedure was
repeated for each locus in a round robin fashion. These allelic
frequencies were used to calculate the unique genotype probabil-
ity, as given by PGEN. The PSEX was derived using binomial
regression of PGEN [18].
The presence of overall multilocus linkage disequilibrium (LD=
non random association of alleles occurring at different loci) was
assessed with LIAN software version 3.5 [19]. The Standardized
Index of Association (IA
s) was estimated as a measure of linkage in
the population, and the significance was tested using the Monte
Carlo method. The presence of linkage disequilibrium was
assessed on monoclonal infections and unique haplotypes.
The distribution of the haplotypes in time was analyzed. The
eBURST software (version 3) was used to group haplotypes based
on their filiations to each other [20]. Different but related
haplotypes were grouped. Two arbitrary criteria to assign
haplotypes to different groups were applied, either 15 identical
loci out of 16 or at least 11 identical loci [10].
Results
Fifty-one P. vivax patients were recruited between March and
May 2008, and followed up monthly for one year. Males (n= 26)
and females (n= 25) were equally represented and the median age
was 15 years (range: 2–80 years old). The geometric mean of the
parasite density at D0 was 1171 parasites/ ml (range 12–9145).
During the first 28-day follow-up, no parasite recurrence were
observed, except in a 67 years old woman who had at day 28 a sub-
patent and asymptomatic P. vivax infection that spontaneously
cleared before the following monthly visit. All patients but one who
left the study area after day 120 completed the 12-month follow up,
totaling 604 person-months at risk. Among the 657 follow up
samples analyzed, 84 recurrent P. vivax infections were identified by
PCR, among which only 26% were detected by microscopy (22
patent infections), and even less (18 episodes) were associated with
malaria symptoms (fever +/2 splenomegaly). Five patients had
more than one patent recurrence. The risk of P. vivax recurrences
(sub- or patent infections) was not correlated with age or sex.
No recurrent infections were observed in 22 (43%, 22/51)
patients (median age 16 years old). Among the 29 patients (57%,
29/51, median age 15 years old) who experienced a total of 84 P.
vivax recurrences, 13 had one episode and 16 more than one, with 3
patients with up to seven recurrences. About half of the patients with
recurrent infections (14/29) had them over two or more consecutive
months, all of them sub-patent and asymptomatic (Table 1). In three
patients the sub-patent infection was followed by a patent infection
within the following month while in all other patients the infection
was cleared without treatment (Table 1). The overall person
infected month (PIM) rate was estimated at 13 per 100 person-
months, i.e. an average 1.6 months of infection. When considering
only the 29 patients with recurrences, the PIM was 22.7/100
person-months, i.e. an average of 2.7 months of infection. The risk
(Kaplan Meier estimate, KME) of having a P. vivax recurrence
(patent and sub-patent) after one year was 59%, with 203 days as the
median survival time to first recurrence. When considering only
Common P. vivax Recurrences after Radical Treatment
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patent infections the risk was 30% (Figure 1) with half of the primary
patent recurrences occurring within the first 70 days of follow up.
Patent recurrent infections tended to occur mainly during month
two to four, with a tendency to decrease with time, while sub-patent
infections were observed throughout the whole follow up period
(Figure 2). The risk of recurrence was higher in Santa Rita (KME
risk = 69%, median time =154 days) than in the other four villages
(KME risk = 53%, median time: 362 days) (logrank test p= 0.34,
a=0.05). Though not significant, this difference may be due to the
non-availability of Insecticide-treated nets in Santa Rita at the time
the study was carried out.
Complexity of the parasite population
The median expected heterozygosity (He) was 0.56, with a wide
range of diversity in the different loci (ranging from 0 to 0.84)
(Table 2). The population genotyping characteristics of day 0
samples have already been published elsewhere [21]. The He for
samples obtained during the follow up were comparable to those
obtained for day 0 though the monthly follow up samples carried
additional alleles at MS8 and MS16 as also indicated by the allelic
richness (Table 2). This probably explains the small but significant
genetic difference (h=0.015, p= 0.0027) between day 0 and
monthly follow up samples.
Only seven polyclonal infections at day 0 and three during the
follow up period were observed. Most infections were monoclonal,
suggesting little outbreeding. Indeed, strong linkage disequilibrium
(ISA=0.29, p,1.10
24) was observed and remained significant
when considering only the unique haplotypes (ISA=0.21,
p,1.1024). From the monoclonal samples, 68 had complete
genotypes among which 38 distinct haplotypes were identified.
The frequencies of the individual haplotypes was low with H12
having the highest frequency (10%). Twenty-three haplotypes
occurred only once (Figure 3) while 15 haplotypes were observed
in more than one malaria episode. From these 15 haplotypes 12
Table 1. Chronogram of the 29 patients with P. vivax recurrences.
2008 2009
PatientVillage Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr
1 Manacamiri X S
2 Manacamiri X S
3 Manacamiri X S S S S
4 Manacamiri X S
5 Manacamiri X P S S S S* S
6 Manacamiri X P S S S S
7 Manacamiri X S S S S S S S*
8 Manacamiri X S
9 Manacamiri X S
10 Manacamiri X P*
11 Lupuna X P P S
12 Lupuna X S S
13 Lupuna X P
14 Fray Martin X P S
15 Fray Martin X P* S* S S* S
16 Fray Martin X P
17 San Pedro X S
18 San Pedro X P* P P
19 Santa Rita X S S S S*
20 Santa Rita X P S S P *
21 Santa Rita X P S S S * S S S
22 Santa Rita X S* S S*
23 Santa Rita X S P P*
24 Santa Rita X* S*
25 Santa Rita X P
26 Santa Rita X P *
27 Santa Rita X S S S S S* S
28 Santa Rita X P * S P P * S
29 Santa Rita X S
X= time of enrolment in the study, S = sub-patent infection, P = patent infections,
* = indicate positive ELISA indicating a recent sporozoite inoculation. Two patients had a positive CSP ELISA at day 0 (April) though no recurrent infections were
reported.
doi:10.1371/journal.pone.0016257.t001
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were spread over different months, suggesting little temporal
clustering. The probability of having identical haplotypes resulting
from a different sexual reproduction was low (average
psex = 5.25610
24), indicating the existence of a common ancestor
and a clonal propagation as result of inbreeding. The genetic
relatedness among haplotypes was calculated with eBURST. Five
clusters of related haplotypes and 20 singletons were identified
when the haplotypes within these clusters carry identical alleles in
at least 15 loci and decreased to three clusters and six singletons
when the criterion of at least 11 loci was applied [10]. No temporal
clustering for related haplotypes was observed.
For the remaining infections (n = 67), the haplotypes could not
be retrieved as they were either polyclonal (n = 10) or no allele was
obtained (n= 57) for one or more loci, even after repeating the
PCR. No amplification could be obtained for 13 of the 84
recurrent infections, all of them sub-patent and asymptomatic,
despite a positive species specific PCR.
Equality versus heterology of recurrent infections
Out of the 71 recurrent infections for which genotyping data
was obtained, 82% (n= 58) carried alleles different from those at
day 0. Only three recurrent infections had a fully related genotype
Figure 2. Monthly prevalence of P. vivax patent, sub-patent infections and of anti-CSP antibodies, and monthly rainfall.
doi:10.1371/journal.pone.0016257.g002
Figure 1. Kaplan-Meier survival analysis showing the probability of remaining free of P. vivax infection (A, patent and sub-patent; B,
only patent) during one-year of follow up.
doi:10.1371/journal.pone.0016257.g001
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with the infection at day 0. All fully related infections occurred
within the first 6 months of follow up. In 10 infections, the
genotypes were incomplete, though the alleles present were
identical to those at day 0. The incomplete genotypes were
analyzed assuming that all incomplete genotypes were either a)
fully related or b) different compared to the genotype obtained at
day 0. Consequently, the proportion of recurrences with a
different genotype ranged between 82% and 96%. Out of the 22
patent infections, 18 were different from those at day 0.
In 30 recurrent episodes (42%, 30/71), the genotype differed
within the same patient from all previous infections; 18 occurred
during the first recurrent episode and within the first three months
of follow up. Seventeen episodes (24%, 17/71) had a similar
genotype with one of the earlier P. vivax episode, while for 24
infections (34%) incomplete haplotypes were obtained in which all
present alleles were similar to all previous infections. When
assuming that incomplete haplotypes were either fully related or
different, the proportion of recurrences with genotypes different
from all previous infections ranged between 42% and 76%. When
considering only patent infections (n = 22), 16 (73%) were different
from all previous infections while six were fully related to one or
more previous infections.
Antibody prevalence against the circumsporozoite
protein
All blood samples PCR positive for P. vivax were analyzed to
detect the presence of anti-CSP antibodies. The OD values were
generally low (0.07–1.3); 6% (3/51) samples collected at day 0 and
21.4% (18/84) at the time of recurrent infection were positive for
anti-CSP antibodies. No significant association between anti-CSP
antibodies and unrelated genotypes, sex or age was found. The
majority of positive samples (60%, 11/18 during follow up and
2/3 at day 0) had been collected in individuals from Santa Rita.
Seroprevalence increased with increasing rainfall while patent
infections showed an opposite trend, suggesting that during the
early months of follow up the observed recurrences may have been
relapses (Figure 2).
Discussion
Despite the low transmission, a substantial number of recurrent
P. vivax infections (patent and sub-patent) were observed after the
supervised administration of the recommended radical cure
regimen. Unlike previous P. vivax cohort studies in which blood
samples were collected only on symptomatic individuals
[10,14,22–25], our cohort patients were systematically examined
every month and blood samples collected regardless of symptoms,
allowing for the detection of asymptomatic infections, a common
occurrence in the Amazon Basin [2,3,26–28]. Microscopy
detected only 26% of the infections identified by PCR. In regions
were sub-patent recurrences are frequent, evaluation of treatment
efficacy based on clinical signs and microscopy might be
insufficient and likely underestimate the true number of recurrent
infections. Consequently the human reservoir is probably much
larger than previously thought. As indicated by the high
proportion of sub-patent and asymptomatic infections, partial
immunity could be induced despite the low transmission.
Moreover, in several patients P. vivax infections remained sub-
patent and asymptomatic for several consecutive months until
spontaneous clearance without treatment. In only three patients
the sub-patent infection became patent and was treated. The
median survival time to the first relapse was about six months
when considering all infections and the majority of patent
infections occurred within three months of follow up, which is
consistent with relapse patterns previously reported in Latin
America [6,9,10,29]. The substantial proportion of individuals
(43%, 22/51) in the cohort who never experienced a recurrent
infection throughout the follow up period suggests either a
heterogeneous exposure or risk to P. vivax infections or an
infection with PQ susceptible parasites with corresponding
clearance of hypnozoites [2,30,31]. Alternatively, recurrent
infections in these individuals may have been missed by the
monthly sampling and cleared by the immune system before being
detected.
Although, comparison between different studies is difficult,
given the variation in methodology, the observed parasite
population diversity and polyclonality was lower than previously
reported in 2003 and 2006 for parasite populations in the same
region of Peru and in the bordering Brazilian Amazon province
[10,21,22,31]. For the latter, the difference could be explained by
the variability of malaria endemicity found in the Amazon region
[27,28,30]. In Peru, we observed a lower diversity and
polyclonality of the parasite population in 2008 compared to
previous studies done in 2003 and 2006. This could be explained
by the decreasing trend in malaria incidence [4,21,31]. However,
the difference with the 2003 study may also be due to the different
molecular markers used for the genotyping [31].
The strong linkage disequilibrium observed suggests little out-
breeding as a result of the low transmission and the paucity of
polyclonal infections [21]. Structuring our haplotypes with
eBURST showed relatively few groups and singletons, indicating
that the circulating haplotypes are closely related to each other
and support the clonal population structure. The absence of
temporal clustering of specific haplotypes could be explained by
the little outbreeding, the activation of hypnozoites and by the
presence for long periods of undetected sub-patent infections. This
Table 2. Genetic diversity of the 135 positive P. vivax samples
analyzed.
Gene diversity (He6) Allelic Richness
Locus Full D0* MF Full D0 MF
MS1 0.10 0,20 0.04 2.99 2,00 1.98
MS2 0.68 0,65 0.69 4.00 3,99 4.00
MS3 0.61 0,67 0.56 3.98 3,00 3.95
MS4 0.44 0,36 0.49 4.00 3,00 4.00
MS5 0.28 0,27 0.29 2.00 2,99 2.00
MS6 0.62 0,64 0.62 5.96 5,00 4.94
MS7 0.00 0,00 0.00 1.00 1,00 1.00
MS8 0.84 0,74 0.84 12.00 8,00 9.00
MS9 0.77 0,74 0.76 7.00 6,00 6.00
MS10 0.59 0,53 0.63 5.00 4,00 4.00
MS12 0.68 0,64 0.70 6.93 6,00 4.00
MS15 0.51 0,51 0.51 5.98 5,98 4.00
MS16 0.65 0,71 0.62 11.90 5,99 8.82
MS20 0.72 0,75 0.71 6.95 5,00 5.86
Pv6635 0.75 0,72 0.76 8.00 6,00 7.00
Pvsal 0.67 0,69 0.65 7.99 6,00 7.90
Average 0,56 0,55 0.55 5.98 4,62 4.90
*Already published in [21]. MF=monthly follow-up. uHe: expected
heterozygosity.
doi:10.1371/journal.pone.0016257.t002
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contrasts with the situation described in the Brazilian Amazon
where temporal clustering occurs [10,22].
Despite, the clonal population structure, a small though
significant genetic differentiation between monthly follow up and
day 0 was found, possibly because recurrent infections carried new
alleles not present or detected at day 0, in MS8 and MS16 as
indicated also by the allelic richness. Heterologous activation of
hypnozoites or new infections may explain this observation. The
majority of recurrent infections carried a genotype different from
that at day 0 while fewer differences were observed when
comparing with all previous episodes within the individual patient.
Several individuals carried sub-patent P. vivax infections for
several months, many of them with the same haplotype, possibly
due to a single parasite clone. However, in three of these
individuals new haplotypes occurred, without any indication of
exposure to new infection, i.e. no anti-CSP antibodies were found,
Figure 3. Distribution of the 38 distinct haplotypes over the different episodes (n=68) by calendar month.
doi:10.1371/journal.pone.0016257.g003
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suggesting that these infections may have originated from liver
forms. However, the sensitivity of the CSP ELISA test is not
optimal (60–77%) and exposure to new infections cannot be
categorically ruled out [32–34]. Indeed, the OD of the CSP
positive samples were generally weak, an expected result when
considering the low number of sporozoites per inoculation and the
short time they circulate in the blood stream [33]. In addition, the
peptide which corresponded to the central repeat domain is
analogue to the VK210 type of CSP, while in the Amazonian
regions the two other variant, VK247 and P. vivax-like, are present
[35,36]. Nevertheless, positivity corresponded to the malaria
transmission dynamics, indicating that it could be used as a proxy
for transmission intensity [37–40]. The use of CSP ELISA as an
indicator of individual exposure to infection may be more
questionable as there was no correlation between CSP positivity
and occurrence of different haplotypes. This could be due to
activation of heterologous hypnozoites while new infections could
carry similar genotypes given the observed clonal population
structure.
Currently, no data is available on the length of time sub-patent
infection remain circulating in the blood stream and on the role of
new inoculations and hypnozoites to maintain them. Probably, the
balance between the natural acquired immunity and parasite
factors such as its antigenic variation is important. The clonal
population structure with the low parasite population diversity
probably contributed to the suggested rapid acquisition of
immunity. The exact role of asymptomatic/sub-patent carriage
in maintaining the transmission needs to be further evaluated.
Though the capability of asymptomatic carriers to transmit is 22-
fold lower than in symptomatic individuals, the chronic nature and
the larger reservoir of the asymptomatic infections could
compensate the lower transmissibility [41].
The proportion of incomplete haplotypes in this study was
substantial and can be explained by the numerous sub-patent
infections whose density was so low that they could not be fully
genotyped. Therefore the establishing with certainty their relation
with previous infections was not possible. This was an important
limiting factor for the analysis of genotype relatedness within a
patient’s subsequent episodes. Whole genome amplification before
genotyping or a nested PCR protocol could improve the sensitivity
of the test and possibly reduce the proportion of incomplete
haplotypes [42,43].
Treatment efficacy at day 28 was high; just one patient had a
sub-patent infection that was identified only retrospectively and
hence not treated. Nevertheless, the following month this patient
did not have any infection as detected by PCR, indicating that the
day 28 infection had been successfully treated. However, the
absence of infection at day 28 does not necessarily exclude CQ
resistance, low levels of tolerant parasites might still be cleared by
the host immunity. Chloroquine resistant P. vivax cases have been
observed in Peru [44] and the recurrent infections beyond day 28
with the genotype fully related to day 0 may suggest that some
parasites may be CQ resistant. However, it is impossible to make
this statement with certainty because CQ plasma levels for our
cohort are not available. The observed clonal population structure
in Peru might represent a risk for the rise and spread of drug
resistance in this area [45].
In conclusion, despite supervised radical cure treatment, several
patients experienced over a 1-year period P. vivax recurrent
infections, most of them asymptomatic and even sub-patent.
Multilocus genotyping was difficult because of the low parasite
densities. Nevertheless, infections with the same or related
haplotypes were not clustered in time and were shared among
different episodes and patients, a finding probably due to their
chronic nature. Moreover, analysis of the parasite population
structure suggested little out-breeding with few polyclonal
infections, indicating low transmission. Indeed, ELISA results
correlated well with the low risk of infection at population but not
at individual level. Further optimization and validation of the
ELISA test is needed. Serology and PCR based tools could be
helpful in areas like Peru where, despite appropriate treatment,
individuals with a P. vivax infection may still represent an
important parasite reservoir for maintaining transmission. Any
elimination effort should consider such a hidden reservoir.
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